Emerging Technologies in Scar Management: The Role of Allogeneic Cells
- PMID: 36351100
- Bookshelf ID: NBK586054
- DOI: 10.1007/978-3-030-44766-3_51
Emerging Technologies in Scar Management: The Role of Allogeneic Cells
Excerpt
Scars caused by burns, chronic ulcers from diabetes, infections, skin cancer surgery, and other genetic or somatic disease could require effective treatment to avoid functional and psychological troubles and even mortality. Most of the current treatments aim to reduce local inflammation but not to prevent scarring. Herein, we discussed about emerging technologies in scar management using allogeneic cell therapy. The industrialised allogeneic cell therapy products and the clinical trials using keratinocytes, fibroblasts or MSCs demonstrated acceleration of skin cell migration and proliferation, control wound scarring, immunomodulatory properties and improved angiogenesis. In addition, allogeneic cell transplants offered the possibility of large pre-fabrication, cryo-preservation, for instantaneous use and repeated applications. Current research exploring allogeneic cell therapies for scar treatment are focusing on grafting of epidermal sheets, cellular dermal substitutes and reconstructed skin equivalent and cell intradermal injections. Advances in knowledge in therapeutic potentials of allogeneic injected cells give rise to new therapeutic approaches such as administration of allogeneic cell-derived extracellular vesicles.
Copyright 2020, The Author(s).
Sections
- 51.1. Background
- 51.2. Allogenic Cell Therapy Studied in Scar Management Field
- 51.3. Human Allogeneic Epidermal Sheets
- 51.4. Cellular Dermal Substitutes and Human Dermal Fibroblasts Therapy
- 51.5. Human Skin Equivalent
- 51.6. Bioprinting of Skin
- 51.7. Injections of Mesenchymal Stromal Cells (MSCs) for Skin Regeneration
- 51.8. Promising Embryonic(-Like) Stem Cells Therapy for Scar Treatment
- 51.9. Conclusion/Discussion
- References
Similar articles
-
Using paracrine effects of Ad-MSCs on keratinocyte cultivation and fabrication of epidermal sheets for improving clinical applications.Cell Tissue Bank. 2018 Dec;19(4):531-547. doi: 10.1007/s10561-018-9702-5. Epub 2018 Aug 13. Cell Tissue Bank. 2018. PMID: 30105667
-
[Clinical study of cell sheets containing allogeneic keratinocytes and fibroblasts for the treatment of partial-thickness burn wounds].Zhonghua Shao Shang Za Zhi. 2020 Mar 20;36(3):171-178. doi: 10.3760/cma.j.cn501120-20191113-00426. Zhonghua Shao Shang Za Zhi. 2020. PMID: 32241042 Chinese.
-
Allogeneic fibroblasts in dermal substitutes induce inflammation and scar formation.Wound Repair Regen. 2002 May-Jun;10(3):152-60. doi: 10.1046/j.1524-475x.2002.10901.x. Wound Repair Regen. 2002. PMID: 12100376
-
Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.Philos Trans R Soc Lond B Biol Sci. 2004 May 29;359(1445):839-50. doi: 10.1098/rstb.2004.1475. Philos Trans R Soc Lond B Biol Sci. 2004. PMID: 15293811 Free PMC article. Review.
-
Tissue-engineered skin. Current status in wound healing.Am J Clin Dermatol. 2001;2(5):305-13. doi: 10.2165/00128071-200102050-00005. Am J Clin Dermatol. 2001. PMID: 11721649 Review.
References
-
- Cubo N, Velasco D, Jorcano JL, Garcia M, del Cañizo JF. 3D bioprinting of functional human skin: production and in vivo analysis. Biofabrication. 2016;9(1):015006. - PubMed
-
- Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy [Internet]. 2016;18(2):160–71.. Available from: https://doi.org/10.1016/j.jcyt.2015.10.011 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources